Growing number of devices set to transform glaucoma treatmentMinimally invasive glaucoma surgery (MIGS) is the latest development in the treatment of glaucoma. With two MIGS devices already approved in the United States, there are a variety of novel devices that have the potential to transform the treatment of glaucoma.
Santen to acquire InnFocus, developer of glaucoma drainage implantSanten Pharmaceutical will soon acquire InnFocus, developer of a glaucoma implant device (InnFocus Microshunt), for $225 million, according to a definitive agreement from the two companies.
Device makers swing for fence with new technologiesDevice manufacturers presenting new implants and technologies to treat glaucoma. As the industry moves from 1.0 devices to 2.0 devices, this will be a transformative time in the way physicians treat patients.
MIGS making big difference in glaucoma managementMicroinvasive glaucoma surgery devices already have transformed the management of glaucoma and will have a bigger impact in the future considering the options in the investigational pipeline and the opportunities they present.
New glaucoma devices bring new dimension of treatment
MIGS devices show encouraging initial results
InnFocus reaches 75-patient treatment milestoneTreatments for InnFocus Inc.’s FDA phase I clinical trial of the InnFocus MicroShunt glaucoma drainage implant have now reached the required 75 patients.